Article info
PDFInflammatory Bowel Disease
Orals
OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study
Citation
OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study
Publication history
- First published June 16, 2019.
Online issue publication
June 16, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions